Decagon Announces Commercial Pilot with Deutsche Telekom and Strategic Investment from T.Capital to Fuel Enterprise Growth
WEB SUMMIT 2025 – Decagon, the leader in conversational AI agents for concierge customer experiences, today announced a commercial pilot with global telecommunications provider Deutsche Telekom, as well as a strategic investment from T.Capital, the corporate venture arm of Deutsche Telekom.
Deutsche Telekom is the world’s largest telecommunications provider by revenue and serves hundreds of millions of mobile customers across the globe. T.Capital provides early- and late-stage strategic capital to companies that have synergies with parent Deutsche Telekom.
“Decagon’s powerful AI is helping businesses deliver an exceptional customer experience,” said Jonathan Abrahamson, Chief Product & Digital Officer at Deutsche Telekom. “The company's innovative approach fits perfectly to our own vision to elevate customer experiences through technology, and we look forward to both our commercial pilot and joining the roster of top-flight investors fueling the company’s impressive product velocity and enterprise growth trajectory.”
“Deutsche Telekom helps millions of people connect with each other in meaningful ways, every single day. We’re proud to play a part in helping them do just that, and we are excited for the holistic partnership with T.Capital as we continue scaling our enterprise operations,” said Jesse Zhang, co-founder and CEO of Decagon.
The announcement was made as Web Summit 2025 kicks off in Lisbon, where Decagon co-founder and CEO Jesse Zhang will give marquee talks about how Decagon is quickly empowering many of the world’s most respected enterprise companies to build, optimize, and scale AI agents that work seamlessly across chat, email, and voice to deliver the always-on concierge experiences customers deserve. Attendees can find him on both the AI Summit Stage and Centre Stage:
- Tuesday, November 12 @ 3:55pm GMT | AI Summit Stage
Closing keynote: Decagon is winning the enterprise–here's how - Wednesday, November 13 @ 12:40pm GMT | Centre Stage
Panel: From demos to deployment: The enterprise AI journey
About Decagon
Decagon empowers the world’s leading enterprise companies to build, optimize, and scale AI agents that give customers the always-on concierge experiences they deserve. Founded in 2023 and launched in the summer of 2024, Decagon is based in San Francisco, with offices in New York City and London. For more information, visit www.decagon.ai.
About Deutsche Telekom
Deutsche Telekom is one of the world's leading integrated telecommunications companies, with more than 261 million mobile customers, 25 million fixed-network lines, and 22 million broadband customers. For more information, visit the Deutsche Telekom corporate information homepage.
About T.Capital
T.Capital manages over €2.3 billion in assets on behalf of Deutsche Telekom across both Venture Capital and Growth/Buyout. The VC team makes initial investments of €1–15 million in Series A to C rounds across the US, Europe, and Israel. While industry- and business model-agnostic, the firm focuses on themes such as AI & cloud infrastructure, security, consumer, and connectivity. By backing ambitious founders, T.Capital provides access to Deutsche Telekom’s infrastructure, joint go-to-market opportunities, commercial resources, and global network. Recent investments — alongside Decagon — include n8n (workflow automation), 11Labs (voice synthesis and speech AI), Perplexity (AI-native search), or Airalo (global eSIM marketplace).
View source version on businesswire.com: https://www.businesswire.com/news/home/20251110484211/en/
Contacts
MEDIA CONTACTS
Decagon: Emilie Cole emilie.cole@decagon.ai
Deutsche Telekom: Verena Fulde verena.fulde@telekom.de
T.Capital: Karine Peters karine.peters@dtcp.capital
Please reach out to all contacts in correspondence.
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom